Retina/Vitreous News

The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.

PARK CITY, Utah — APX3330, an investigational systemic treatment for diabetic retinopathy, showed encouraging outcomes in the phase 2 ZETA-1 trial, paving the way to phase 3.

Pars plana vitrectomy with internal limiting membrane peeling for macular hole closure is better than pars plana vitrectomy without internal limiting membrane peeling, according to a study.

Patients with epiretinal membrane after proliferative vitreoretinopathy repair may benefit from early peeling, according to a study presented at the American Society of Retina Specialists annual meeting.

In this Healio Video Perspective from the ASRS meeting, Carl C. Awh, MD, FASRS, of Tennessee Retina discusses the phase 3 Pagoda trial investigating the port delivery system with ranibizumab for diabetic macular edema.

Merck has announced the acquisition of all outstanding shares of EyeBio, making it a wholly-owned subsidiary, according to a company press release.

A 58-year-old African American man was referred to the retina clinic with a complaint of progressive blurred vision in the left eye. He was functionally monocular due to a history of refractive amblyopia in the right eye.

Luxturna maintained long-term improvements in ambulatory vision, light sensitivity and visual field in patients with biallelic RPE65 mutation-associated retinal diseases, according to a study.

In this Healio Video Perspective from the ASRS meeting, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the phase 3 program for Axpaxli, an axitinib implant for wet age-related macular degeneration.

In this Healio Video Perspective from the ASRS meeting, Danny Mammo, MD, of Cole Eye Institute discusses the real-world effect of triamcinolone acetonide on IOP in patients with uveitic macular edema.